Janux doses first patient in Phase 1 trial of JANX013 in metastatic prostate cancer
JANX•Program expands PSMA-focused prostate cancer strategy
The trial tests JANX013 with JANX007, aiming to strengthen and prolong anti-tumor immune responses through tumor-restricted CD28 co-stimulation.
The program expands Janux’s PSMA-focused prostate cancer strategy, with plans to study JANX013 alongside other portfolio candidates over time.
Phase 1 trial starts for JANX013 in metastatic prostate cancer
Janux Therapeutics dosed the first patient in a Phase 1 trial of JANX013 for metastatic castration-resistant prostate cancer.
Results have not been presented; the study will generate initial safety, drug-behavior, immune-activity, and early efficacy readouts.
